Navigation Links
Martek Announces Fourth Quarter and FY 2010 Financial Results
Date:12/8/2010

ula customer.  With the signing of this agreement, customers representing a total of 52% and 44% of Martek's current infant formula sales are now under contract through at least 2014 and 2015, respectively.
  • New Scientific Data/Recommendations Published on DHA and ARA – In The Journal of Pediatrics (December 2010) Dr. C. Jensen and co-investigators reported 5-year follow-up data in children who had been breastfed as infants.  In the original study, nursing mothers received either 200 mg DHA per day or a placebo for 4 months as part of the randomized double blind study.  Milk lipid and infant plasma phospholipid DHA contents were 75% and 35% higher, respectively, at 4 months postpartum in the supplemented group. The children of supplemented mothers were previously shown to exhibit better psychomotor development at 30 months of age as compared to their unsupplemented counterparts.  In the current report, the 5-year old children whose mothers received DHA performed better than the unsupplemented group on a test of sustained attention.  The importance of Dr. C. Jensen's findings is highlighted by Dr. M. Clandinin and Dr. P. Larsen in an accompanying The Journal of Pediatrics editorial.  The editorial entitled "Docosahexaenoic Acid Is Essential to Development of Critical Functions in Infants" reviews and emphasizes the importance of early and continued supplementation of DHA for infants and children under normal as well as special medical circumstances.  Martek's life'sDHA was used in the study.  The study was also supported by grants from Martek and the U.S. Department of Agriculture/National Research Initiative; however, Martek did not have input into the conduct or reporting of the study or the editorial.  

  • Financial Guidance For the first quarter of fiscal 2011, Martek is providing the following revenue guidance:Three months ended January 31, 2011$ in
    '/>"/>

    SOURCE Martek Biosciences Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related biology technology :

    1. Martek to Present at Upcoming Citi Small / Mid Cap Conference
    2. Martek to Present at Upcoming UBS Conference
    3. Martek Announces Third Quarter FY 2010 Financial Results
    4. Martek Announces Fourth Quarter and FY 2009 Financial Results
    5. Martek Signs Sole-Source Supply Agreement with Fonterra
    6. Martek to Announce Fourth Quarter and Fiscal Year 2009 Results
    7. Martek Announces Addition to Its Board of Directors
    8. Martek to Present at Two Upcoming Investor Conferences
    9. Martek Announces Settlement of Patent Dispute with Capsugel France
    10. Federal Circuit Rules in Marteks Favor in Appeal of Patent Infringement Case
    11. Martek Signs Sole-Source Supply Agreement with Milk Powder Solutions
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/21/2015)... Seventh Wave Laboratories, a consulting-based contract research ... products and medical devices, announced the purchase of 19 ... sq. ft. building more than three times the size ... renovations will begin immediately and the gradual transition of ... September. , “We are excited about this growth,” ...
    (Date:5/21/2015)... May 21, 2015  The EveryLife Foundation for ... (R-UT) and Amy Klobuchar (D-MN) today ... Cures & Treatments, or OPEN ACT. ... advocacy organizations, this bipartisan legislation promises to rapidly ... to rare disease patients by incentivizing drug makers ...
    (Date:5/21/2015)... 2015 As part of its philanthropic ... Sun Health Foundation funded a $3.25 million project to ... with the most up-to-date features and technology. , The ... pharmacy's 45 staff members will begin moving from the ... the coming days. , The current pharmacy has ...
    (Date:5/20/2015)... FRANCISCO, Calif. , May 20, 2015 /PRNewswire/ ... ) today presented preliminary data demonstrating the ability ... idiopathic pulmonary fibrosis (IPF) from other interstitial lung ... findings suggest the classifier,s potential to help thousands ... to resolve ambiguity in IPF diagnosis – a ...
    Breaking Biology Technology:Seventh Wave Laboratories Purchases Building for Expansion, Upcoming Move 2Seventh Wave Laboratories Purchases Building for Expansion, Upcoming Move 3Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5
    ... for Bevasiranib Broadly Covers siRNA Targeting of, VEGF Expression, Further Strengthening ... ... MIAMI, March 18 OPKO Health, Inc. (Amex: OPK ),today announced ... and Trademark Office (USPTO) for methods related to the use and,administration of ...
    ... safety, effectiveness, and environmental impact of removing pollutant, ... ... products-, BOURNE, Mass., ... company has closed the first,tranche of a $2.5 million institutional financing ...
    ... Mich., March 18 Neogen Corporation,(Nasdaq: NEOG ) announces the following ... When: March 25, 2008 11:00 EDT, Where: ... Simply log on to the web at the address ... of Neogen Corporation, +1-800-234-5333. If you are unable to participate during ...
    Cached Biology Technology:OPKO Health Announces Issuance of U.S. Patent Covering the Use and Administration of Certain Anti-VEGF siRNA's, Including Its Phase III Compound Bevasiranib 2OPKO Health Announces Issuance of U.S. Patent Covering the Use and Administration of Certain Anti-VEGF siRNA's, Including Its Phase III Compound Bevasiranib 3OPKO Health Announces Issuance of U.S. Patent Covering the Use and Administration of Certain Anti-VEGF siRNA's, Including Its Phase III Compound Bevasiranib 4Environmental Operating Solutions Completes Initial Tranche of $2.5 Million Institutional Financing 2Environmental Operating Solutions Completes Initial Tranche of $2.5 Million Institutional Financing 3Environmental Operating Solutions Completes Initial Tranche of $2.5 Million Institutional Financing 4
    (Date:5/21/2015)... May 21, 2015 According ... Market by Solutions (Hardware, Software, Services), by Applications (Surveillance ... others), by End-Users (Military & Defense & Commercial) ... Thermal Imaging Market is expected to grow from ... 2020, at a Compound Annual Growth Rate (CAGR) ...
    (Date:5/20/2015)... OXFORD, Conn. , May 20, 2015 ... "Company") announces that its wholly owned subsidiary, 3D-ID LLC, ... contractor under Team Battelle for the biometrics technology portion ... Unrestricted Suite Contract from the Department of the Army. ... facial recognition products developed for government, law enforcement and ...
    (Date:5/19/2015)... 2015 Research and ... of the  "Genetic Testing Market Outlook 2018" ... , ,A recent report, Genetic Testing Market ... the current and future genetic testing market. ... working principles and types are covered in ...
    Breaking Biology News(10 mins):Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3Global Genetic Testing Market Outlook 2018 2
    ... from a mutation in one genome are complicated enough, ... genomes: the DNA in the nucleus and in the ... genomic disconnects cause disease. In a step in that ... traced one such incompatibility in fruit flies down to ...
    ... ten million, with dogs producing approximately 1,000 tonnes of excrement ... as a major source of the parasite egg, Toxocara ... humans. The aim of the study, led by Dr ... of Veterinary Sciences and published in the international scientific journal, ...
    ... Here,s another reason why you should include olive oil ... the Journal of Leukocyte Biology ... significantly reduces intestinal ischemia (restricted blood supply) and the ... returns). The compound, called "oleuropein aglycone," is the most ...
    Cached Biology News:Mitochondrial mutations: When the cell's 2 genomes collide 2Mitochondrial mutations: When the cell's 2 genomes collide 3Caring for dogs to reduce spread of parasite eggs harmful to humans 2Olive oil component alleviates intestinal ischemia and reperfusion 2
    Porcine Pulmonary Artery Endothelial Cells (PPAEC) (>500,000 cells)...
    ... Fluoroskan Ascent is a dedicated ... for all kinds of assays ... and for clinical applications. Cell ... are all important application areas. ...
    ... latest SpeedVac Concentrator, the SPD series takes ... new modern twist., The SPD121P SpeedVac comes ... for optimizing runs; preventing samples from freezing; ... at the end-users preset level., Standard features ...
    ... personal desktop unit ideal for use in laboratories ... Rotation speed set at 12 rpm , ... , Bottle capacity of four 35 x 150mm ... ,plastic bottles , Consistent, repeatable results achieved ...
    Biology Products: